According to a document released by all five authorities, by 2030, intelligent diagnosis and treatment assistance will be universal in basic terms across China's primary-level medical institutions, including community and village clinics. Meanwhile, hospitals at or above the second grade in China's three-tier hospital system will widely adopt AI technologies such as intelligent medical-imaging diagnosis and clinical decision-making support technologies.

According to the results of the basic research, different medical institutions have selected different imported and domestic brand instruments: 38 domestic and 58 imported.

Bio-Rad Laboratories reported after the close of the market recently thatits second quarter revenues increased 14 percent year over year, driven bygrowth in both its Life Science and Clinical Diagnostics businesses. For the three months end

PerkinElmer, Women Infants Hospital of Rhode Island to Test NIPT System PerkinElmer said recently that it is collaborating with Women Infants Hospital (WIH) of Rhode Island toevaluate the performance of its Vanadis noninvasive prenatal test

Research-stage biopharmaceutical company Enzyvant said today it has partnered with PerkinElmer to offer diagnostic testing for Farber disease to patients and their medical providers. Through its PerkinElmer Genomics laboratory and genetic t

Thermo Fisher Scientific recently reported a 22 percent increase in second-quarter revenues that was partly driven by acquisitions and increased its revenue and earnings guidance for the year for the second time in a row. We achieved excelle

Xiamen Spacegen, a provider of oncology molecular diagnostics products and services in China, said recently that it had received CE marking for six testing kits. These kits include a human thyroid carcinoma RET gene fusions detection kit, wh

Bionano Genomics (hereafter referred to asBionano) was founded in 2004 as a biotechnology company in San Diego, USA. Itsoptical mapping system is the only physical mapping technology that can jointlyassemble and analyze the optical signals

The global POC blood glucose monitoring devices market is expected toreach USD 2.03 billion in 2022, driven mainly by public and private initiativesto reduce diabetic cases. However, the high cost associated with diabetesmanagement is one o

MA activity in the liquid biopsy space is picking up as Bio-Techne said it will acquire Exosome Diagnostics for $250 million plus $325 million in potential milestones. Waltham, MA-based Exosome has developed the urine-based test ExoDx Prost

President Donald Trump is trying to shame the largest U.S. drugmaker for hikingpricesafter he earlier said industry players were planning massive price reductions. He said Pfizer and others should be ashamed that they have raised drug price

The global molecular diagnostics market is expected to grow at a CAGR of8.4% from USD 7.71 billion in 2018 to USD 11.54 billion by 2023, driven by theincreasing prevalence of infectious diseases and various types of cancers,rising awareness